Patents by Inventor Edward Thein Htun van der Horst

Edward Thein Htun van der Horst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-C10orf54 antibodies and uses thereof
    Patent number: 11873339
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: January 16, 2024
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
  • RECEPTOR FOR VISTA
    Publication number: 20230243836
    Abstract: The present disclosure provides methods for modulating (e.g., preventing, inhibiting, blocking) the interaction of PSGL-1 and VISTA with agents (e.g., antibodies) that bind to PSGL-1 and/or VISTA.
    Type: Application
    Filed: July 22, 2019
    Publication date: August 3, 2023
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Pierre FERRÉ, Francisco CRUZALEGUI, Noureddine LOUKILI, Olivier DELFOUR, Edward Thein Htun VAN DER HORST
  • ANTI-C10ORF54 ANTIBODIES AND USES THEREOF
    Publication number: 20200385473
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 10, 2020
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sung Young KIM, Leonard G PRESTA, Jan-Willem THEUNISSEN
  • Anti-C10ORF54 antibodies and uses thereof
    Patent number: 10766959
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: September 8, 2020
    Assignee: Pierre Fabre Medicament
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
  • ANTI-C10ORF54 ANTIBODIES AND USES THEREOF
    Publication number: 20200040102
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: July 23, 2019
    Publication date: February 6, 2020
    Applicant: Pierre Fabre Medicament
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sun Young KIM, Leonard G. PRESTA
  • Anti-C10orf54 antibodies and uses thereof
    Patent number: 10421818
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: September 24, 2019
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sun Young Kim, Leonard G. Presta
  • Anti-C10orf54 antibodies and uses thereof
    Patent number: 10414823
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: September 17, 2019
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sun Young Kim, Leonard G. Presta
  • ANTI-C10ORF54 ANTIBODIES AND USES THEREOF
    Publication number: 20190177415
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: December 11, 2015
    Publication date: June 13, 2019
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sung Young KIM, Leonard G PRESTA, Jan-Willem THEUNISSEN
  • ANTI-C10ORF54 ANTIBODIES AND USES THEREOF
    Publication number: 20190031767
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: August 2, 2018
    Publication date: January 31, 2019
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sun Young KIM, Leonard G. PRESTA
  • ANTI-C10ORF54 ANTIBODIES AND USES THEREOF
    Publication number: 20190031768
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: August 2, 2018
    Publication date: January 31, 2019
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sun Young KIM, Leonard G. PRESTA
  • Anti-C10orf54 antibodies and uses thereof
    Patent number: 10100123
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: October 16, 2018
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sun Young Kim, Leonard G. Presta
  • NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20170198031
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: October 20, 2016
    Publication date: July 13, 2017
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Timothy Charles HOEY, Edward Thein Htun van der HORST, Aaron Ken SATO, Yuan Ching LIU, Maureen Fitch BRUHNS, John A. LEWICKI
  • ANTI-C10ORF54 ANTIBODIES AND USES THEREOF
    Publication number: 20160369005
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 22, 2016
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sun Young KIM, Leonard G. PRESTA
  • Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3
    Patent number: 9505832
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: November 29, 2016
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • DDR1-binding agents and methods of use thereof
    Patent number: 9206256
    Abstract: The present invention relates to DDR1 binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of DDR1 and modulate DDR1 activity. The present invention further provides methods of using agents that modulate the activity of DDR1, such as antibodies that specifically bind DDR1, to reduce the tumorigenicity of tumors comprising cancer stem cells by reducing the frequency or number of cancer stem cells in the tumor. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: December 8, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Edward Thein Htun Van Der Horst, Sanjeev H. Satyal
  • Notch1 binding agents and methods of use thereof
    Patent number: 9132189
    Abstract: The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: September 15, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Edward Thein Htun van der Horst, Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
  • ANTI-C16ORF54 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20150231240
    Abstract: The invention provides antibodies that bind C16orf54, including antibody-drug conjugates comprising the antibodies, and methods of use of the antibodies and the antibody-drug conjugates, including for the diagnosis and treatment of cancers.
    Type: Application
    Filed: October 9, 2013
    Publication date: August 20, 2015
    Applicant: IGENICA BIOTHERAPEUTICS, INC.
    Inventors: Guoqing Chen, Sun Young Kim, Jan-Willem Theunissen, Edward Thein-Htun Van Der Horst, David Jackson, Edward Ha, John Lippincott
  • NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20150197563
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: January 20, 2015
    Publication date: July 16, 2015
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Monoclonal antibody that binds human notch2 and notch3
    Patent number: 8980260
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 17, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Polynucleotides encoding Notch receptor antibodies
    Patent number: 8945873
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: February 3, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki